Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Retained Earnings (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Retained Earnings readings, the most recent being -$338.7 million for Q1 2026.

  • Quarterly Retained Earnings fell 720538.3% to -$338.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$338.7 million through Mar 2026, down 720538.3% year-over-year, with the annual reading at -$321.7 million for FY2025, 5.72% down from the prior year.
  • Retained Earnings hit -$338.7 million in Q1 2026 for Ovid Therapeutics, down from -$321.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $1000.0 in Q4 2023 and bottomed at -$338.7 million in Q1 2026.
  • Average Retained Earnings over 5 years is -$166.0 million, with a median of -$238.9 million recorded in 2023.
  • The largest annual shift saw Retained Earnings soared 102.37% in 2023 before it plummeted 30430000.0% in 2024.
  • Ovid Therapeutics' Retained Earnings stood at -$42187.0 in 2022, then soared by 102.37% to $1000.0 in 2023, then plummeted by 30430000.0% to -$304.3 million in 2024, then decreased by 5.72% to -$321.7 million in 2025, then decreased by 5.28% to -$338.7 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Retained Earnings are -$338.7 million (Q1 2026), -$321.7 million (Q4 2025), and -$331.4 million (Q3 2025).